Edith Rosato, RPh, has recently been appointed new CEO of the Academy of Managed Care Pharmacy.
Edith Rosato, RPh, has recently been appointed the new CEO of the Academy of Managed Care Pharmacy (AMCP).
"I am very excited and honored to join AMCP, 1 of the nation's leading organizations in pharmacy and managed care. I believe wholeheartedly in the Academy's mission, and am looking forward to building on the great work that has been already done over the past 2 decades," Rosato said.
Rosato will be responsible for all program, financial, and operational aspects of AMCP, including a $10-million budget and staff of nearly 40 people. "The staff and volunteer leadership are impressive and demonstrate the passion necessary to advance the profession," Rosato said.
Prior to Rosato's 11 years at NACDS, she served as director of customer development for Healthcare Systems, national accounts manager for Wyeth-Ayerst Laboratories, and corporate pharmaceutical buyer for CVS Caremark. "Edith's extensive industry knowledge and excellent leadership experience make her an ideal choice for successfully guiding AMCP into the future and helping us continue to improve healthcare for all," said David Clark, president of AMCP.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Are PBMs Putting GLP-1 Drugs on Their Formularies?
October 11th 2024PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
Read More